Evidence map›Paper›PMID 38966648›Full record

ArticleJournal of general and family medicine2024

Successful treatment of a Morbihan's disease patient after a therapeutic challenge: A case report and comprehensive literature review.

Afsaneh Sadeghzadeh Bazargan, Ali Zare Dehnavi, Abbas Dehghani, Kambiz Kamyab Hesari, Paria Jafari, Azadeh Goodarzi

Abstract readCase Reports
In one paragraph

Article in Journal of general and family medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Afsaneh Sadeghzadeh BazarganDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine Iran University of Medical Sciences (IUMS) Tehran Iran.
Ali Zare DehnaviTehran University of Medical Sciences Tehran Iran.
Abbas DehghaniDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine Iran University of Medical Sciences (IUMS) Tehran Iran.ORCID https://orcid.org/0000-0001-9277-3606
Kambiz Kamyab HesariDepartment of Dermatopathology, Razi Hospital Tehran University of Medical Sciences Tehran Iran.
Paria JafariDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine Iran University of Medical Sciences (IUMS) Tehran Iran.
Azadeh GoodarziDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine Iran University of Medical Sciences (IUMS) Tehran Iran.ORCID https://orcid.org/0000-0002-1249-4429

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Morbihan's disease is a rare condition characterized by chronic facial edema. While its exact cause is unknown, it is thought to involve local cutaneous vascularization and lymphatic drainage imbalance. Traditional treatment options are often ineffective, and no established efficient treatment exists. We present a case study of a 17-year-old male with Morbihan's syndrome who showed resistance to traditional treatments but responded well to a combination of cromolyn sodium nasal spray and oral montelukast after histopathology revealed hyperplasia of plasma cells and mast cells. This combination has not been used before for Morbihan's syndrome. Our review of the literature also provides insight for clinicians seeking to manage this condition.

Indexed as

adult's Morbihan diseasecromolyn sodiummast cellmontelukastMorbihan syndrome

Identifiers

PMID38966648
PMCPMC11221058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.